MA28531B1 - Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 - Google Patents

Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Info

Publication number
MA28531B1
MA28531B1 MA29385A MA29385A MA28531B1 MA 28531 B1 MA28531 B1 MA 28531B1 MA 29385 A MA29385 A MA 29385A MA 29385 A MA29385 A MA 29385A MA 28531 B1 MA28531 B1 MA 28531B1
Authority
MA
Morocco
Prior art keywords
pdea4
pyrazolo
pyridine
inhibitor
composition
Prior art date
Application number
MA29385A
Other languages
English (en)
Inventor
Siegfried Benjamin Christensen Iv
Caroline Mary Cook
Christopher David Edlin
Martin Redpath Johnson
Paul Spencer Jones
Mika Kristian Lindvall
Amyn Pyarali Sayani
Naimisha Trivedi
Lionel Trottet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405893A external-priority patent/GB0405893D0/en
Priority claimed from GB0505214A external-priority patent/GB0505214D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28531B1 publication Critical patent/MA28531B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA29385A 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4 MA28531B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0405893A GB0405893D0 (en) 2004-03-16 2004-03-16 Compounds
GB0505214A GB0505214D0 (en) 2005-03-14 2005-03-14 Compounds

Publications (1)

Publication Number Publication Date
MA28531B1 true MA28531B1 (fr) 2007-04-03

Family

ID=34962723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29385A MA28531B1 (fr) 2004-03-16 2006-10-13 Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4

Country Status (15)

Country Link
US (2) US7709497B2 (fr)
EP (2) EP1735314A1 (fr)
JP (2) JP2007529486A (fr)
KR (1) KR20060130744A (fr)
AR (1) AR048175A1 (fr)
AU (1) AU2005223351A1 (fr)
BR (1) BRPI0508843A (fr)
CA (1) CA2559629A1 (fr)
IL (1) IL178011A0 (fr)
MA (1) MA28531B1 (fr)
NO (1) NO20064450L (fr)
PE (1) PE20060078A1 (fr)
RU (1) RU2378274C2 (fr)
TW (1) TW200602051A (fr)
WO (2) WO2005090354A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2005058892A1 (fr) * 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
AU2005223351A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
KR20090003349A (ko) 2006-04-20 2009-01-09 글락소 그룹 리미티드 화합물
AR061571A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto sal del acido toluenosulfonico de 4-{[6-cloro-3-({[(2- cloro-3-fluorofenil) amino]carbonil} amino)- 2- hidroxifenil]sulfonil] -1- piperazinacarbxilato de 1.1-dimetiletilo, composicion farmaceutica que lo comprende su uso para la fabricacion de un medicamento combinacion farmaceutica con un
CA2659539A1 (fr) 2006-08-01 2008-02-07 Glaxo Group Limited Composes de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de pde4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091553A1 (es) 2008-02-06 2009-10-30 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
AR070562A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
WO2009100169A1 (fr) * 2008-02-06 2009-08-13 Glaxo Group Limited Pharmacophores duals, antagonistes des récepteurs muscariniques et inhibiteurs de l'activité pde4
GB0806900D0 (en) * 2008-04-16 2008-05-21 Dow Corning Fabric care emulsions
ES2566339T3 (es) 2008-06-05 2016-04-12 Glaxo Group Limited Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
ES2433109T3 (es) 2009-01-13 2013-12-09 Glaxo Group Limited Derivados de pirimidin-carboxamida como inhibidores de la Syk cinasa
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
EP2408769A1 (fr) 2009-03-17 2012-01-25 Glaxo Group Limited Dérivés de pyrimidine utilisés comme inhibiteurs de ltk
SI2419087T1 (sl) * 2009-04-13 2013-06-28 Vanangamudi Subramaniam Sulur Medicinska krema na osnovi fusidne kisline, izdelana z uporabo natrijevega fusidata in vsebujoča biopolimer in postopek za njeno izdelavo
CN102459253B (zh) 2009-04-30 2015-03-25 葛兰素集团有限公司 作为pi3-激酶抑制剂的*唑取代的吲唑化合物
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
WO2011067366A1 (fr) 2009-12-03 2011-06-09 Glaxo Group Limited Dérivés d'indazole comme inhibiteurs des pi3-kinases
EP2507223A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Dérivés de benzpyrazole comme inhibiteurs des pi3 kinases
WO2011110575A1 (fr) 2010-03-11 2011-09-15 Glaxo Group Limited Dérivés de 2-[2-(benzo- ou pyrido-)thiazolylamino]-6- aminopyridine, utiles dans le traitement de maladies respiratoires, allergiques ou inflammatoires
WO2012032065A1 (fr) 2010-09-08 2012-03-15 Glaxo Group Limited Dérivés indazole à utiliser dans le traitement d'une infection par le virus de la grippe
JP5965402B2 (ja) 2010-09-08 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩
WO2012035055A1 (fr) 2010-09-17 2012-03-22 Glaxo Group Limited Nouveaux composés
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
CN104487864B (zh) 2012-08-27 2017-06-23 伊莱克斯公司 机器人定位系统
US10448794B2 (en) 2013-04-15 2019-10-22 Aktiebolaget Electrolux Robotic vacuum cleaner
CN105101855A (zh) 2013-04-15 2015-11-25 伊莱克斯公司 具有伸出的侧刷的机器人真空吸尘器
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
EP3057587A1 (fr) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
WO2015055691A1 (fr) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Inhibiteur de pi3k pour le traitement d'une maladie respiratoire
EP3084540B1 (fr) 2013-12-19 2021-04-14 Aktiebolaget Electrolux Robot de nettoyage et methode d'exploitation associee
JP6638988B2 (ja) 2013-12-19 2020-02-05 アクチエボラゲット エレクトロルックス サイドブラシを有し、渦巻きパターンで動くロボットバキュームクリーナ
ES2675786T3 (es) 2013-12-19 2018-07-12 Aktiebolaget Electrolux Control de velocidad adaptativo de cepillo lateral rotatorio
US10617271B2 (en) 2013-12-19 2020-04-14 Aktiebolaget Electrolux Robotic cleaning device and method for landmark recognition
JP2017502371A (ja) 2013-12-19 2017-01-19 アクチエボラゲット エレクトロルックス 掃除領域の優先順位付け
CN105813528B (zh) 2013-12-19 2019-05-07 伊莱克斯公司 机器人清洁设备的障碍物感测爬行
EP3084538B1 (fr) 2013-12-19 2017-11-01 Aktiebolaget Electrolux Dispositif de nettoyage robotisé à fonction d'enregistrement de périmètre
US10231591B2 (en) 2013-12-20 2019-03-19 Aktiebolaget Electrolux Dust container
TW201625247A (zh) 2014-05-12 2016-07-16 葛蘭素史密斯克藍智慧財產權有限公司 用於治療傳染性疾病之醫藥組合物
CN106415423B (zh) 2014-07-10 2021-01-01 伊莱克斯公司 用于检测机器人清洁装置的测量误差的方法
WO2016037636A1 (fr) 2014-09-08 2016-03-17 Aktiebolaget Electrolux Aspirateur robotisé
US10499778B2 (en) 2014-09-08 2019-12-10 Aktiebolaget Electrolux Robotic vacuum cleaner
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
WO2016091291A1 (fr) 2014-12-10 2016-06-16 Aktiebolaget Electrolux Utilisation d'un capteur laser pour la détection d'un type de sol
EP3229983B1 (fr) 2014-12-12 2019-02-20 Aktiebolaget Electrolux Brosse latérale et appareil de nettoyage robotique
EP3234714B1 (fr) 2014-12-16 2021-05-12 Aktiebolaget Electrolux Feuille de route basée sur l'expérience pour un dispositif de nettoyage robotisé
KR102326401B1 (ko) 2014-12-16 2021-11-16 에이비 엘렉트로룩스 로봇 청소 장치를 위한 청소 방법
CN107405034B (zh) 2015-04-17 2022-09-13 伊莱克斯公司 机器人清洁设备以及控制所述机器人清洁设备的方法
CN107920709A (zh) 2015-09-03 2018-04-17 伊莱克斯公司 机器人清洁设备系统
KR20180083323A (ko) * 2015-10-09 2018-07-20 애브비 에스.에이.알.엘. N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
US11169533B2 (en) 2016-03-15 2021-11-09 Aktiebolaget Electrolux Robotic cleaning device and a method at the robotic cleaning device of performing cliff detection
WO2017194102A1 (fr) 2016-05-11 2017-11-16 Aktiebolaget Electrolux Dispositif de nettoyage robotisé
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN110621208A (zh) 2017-06-02 2019-12-27 伊莱克斯公司 检测机器人清洁设备前方的表面的高度差的方法
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR20200058400A (ko) 2017-09-26 2020-05-27 에이비 엘렉트로룩스 로봇 청소 장치의 이동 제어
KR102034538B1 (ko) * 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
RU2134498C1 (ru) * 1998-12-08 1999-08-10 Таран Александр Иванович Контактный узел
ES2258476T3 (es) 1999-09-30 2006-09-01 Neurogen Corporation Ciertos heterociclos sustituidos con alquilendiaminas.
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
MXPA05002887A (es) 2002-09-16 2005-05-27 Glaxo Group Ltd Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
US7117650B2 (en) * 2002-12-09 2006-10-10 Forrest Dockery Hanger system
WO2005058892A1 (fr) 2003-12-19 2005-06-30 Glaxo Group Limited Composes pyrazolo [3,4-b] pyridine et leur utilisation en tant qu'inhibiteurs de la phosphodiesterase
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
AU2005223351A1 (en) 2004-03-16 2005-09-29 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
IL178011A0 (en) 2006-12-31
AU2005223351A1 (en) 2005-09-29
WO2005090352A1 (fr) 2005-09-29
JP2007529464A (ja) 2007-10-25
RU2378274C2 (ru) 2010-01-10
AR048175A1 (es) 2006-04-05
US20080275078A1 (en) 2008-11-06
US7709497B2 (en) 2010-05-04
WO2005090354A1 (fr) 2005-09-29
TW200602051A (en) 2006-01-16
EP1740590A1 (fr) 2007-01-10
RU2006132684A (ru) 2008-04-27
NO20064450L (no) 2006-11-14
CA2559629A1 (fr) 2005-09-29
BRPI0508843A (pt) 2007-08-28
JP2007529486A (ja) 2007-10-25
PE20060078A1 (es) 2006-03-10
EP1735314A1 (fr) 2006-12-27
KR20060130744A (ko) 2006-12-19
US20070280971A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
MA28531B1 (fr) Composition de pyrazolo[3,4-b]pyridine, et son utilisation en tant qu'inhibiteur de pdea4
TWI347844B (en) Sulfoximine-substituted pyrimidines as cdk-and/or vegf inhibitors, their production and use as pharmaceutical agents
IS7913A (is) Pýrasóló[3,4-b]pýridín efnasambönd, og notkun þeirra sem fosfórdíesterasa hindrar
HRP20150474T1 (xx) PIRIDINOM I KINOLINOM SUPSTITUIRANI PIROLO[1,2-b]PIRAZOL MONOHIDRAT KAO INHIBITOR TGF-BETA
SG103382A1 (en) Colored absorbent article
SG103904A1 (en) Colored absorbent article
EP1732906A4 (fr) Composes de 2-aminothiazole utiles en tant qu'inhibiteurs de l'aspartyle-protease
NO20071364L (no) 6H-[l] benzopyrano[4,3-b]-kinoliner og deres anvendelse som østrogenmidler
IL182963A0 (en) Imidazo[1,2-a] pyridine compounds, compositions, uses and methods related thereto
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
ATE382261T1 (de) Flüssige formulierung
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
EP1951231A4 (fr) Derives de camptothecine utiles comme agents chimioradiosensibles
DE60218213D1 (de) Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
EP1778734A4 (fr) Composition de pulverisation comportant un agent de regulation du depot
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
EP1714656A4 (fr) Preparation de l'ed-71
EP1409507A4 (fr) Compositions, procedes et kits se rapportant a remodelin
FR2857363B1 (fr) 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
DE60311273D1 (de) Gemischtes schmuckset
EP1786433A4 (fr) Derives de betulinol utilises en tant qu'agents anti-vih
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
AU2002229859A1 (en) Chemical derivatives and their use as anti-telomerase agent
GB0308157D0 (en) Coloured plasters
SK3861U (sk) Dekoratívna farebná štrukturálna omietka